Join Growin Stock Community!

Assembly biosciences, inc.ASMB.US Overview

US StockHealthcare
(No presentation for ASMB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ASMB AI Insights

ASMB Overall Performance

ASMB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ASMB Recent Performance

0.84%

Assembly biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ASMB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ASMB Key Information

ASMB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ASMB Profile

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Price of ASMB

ASMB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ASMB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.69
PB Ratio
2.56
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.69
PB Ratio
2.56
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ASMB's latest earnings report released?

    The most recent financial report for Assembly biosciences, inc. (ASMB) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ASMB's short-term business performance and financial health. For the latest updates on ASMB's earnings releases, visit this page regularly.

  • How much debt does ASMB have?

    As of the end of the reporting period, Assembly biosciences, inc. (ASMB) had total debt of 2.76M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ASMB have?

    At the end of the period, Assembly biosciences, inc. (ASMB) held Total Cash and Cash Equivalents of 22.53M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ASMB's EPS continuing to grow?

    According to the past four quarterly reports, Assembly biosciences, inc. (ASMB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.72. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ASMB?

    Assembly biosciences, inc. (ASMB)'s Free Cash Flow (FCF) for the period is -15.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.